key: cord-0999498-lz8hm06n
authors: Coléon, Séverin; Wiedemann, Aurélie; Surénaud, Mathieu; Lacabaratz, Christine; Hue, Sophie; Prague, Mélanie; Cervantes-Gonzalez, Minerva; Wang, Zhiqing; Ellis, Jerome; Sansoni, Amandine; Pierini, Camille; Bardin, Quentin; Fabregue, Manon; Sharkaoui, Sarah; Hoest, Philippe; Dupaty, Léa; Picard, Florence; Centlivre, Mireille; Ghosn, Jade; Thiébaut, Rodolphe; Cardinaud, Sylvain; Malissen, Bernard; Zurawski, Gérard; Zarubica, Ana; Zurawski, Sandra M; Godot, Véronique; Lévy, Yves
title: Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine
date: 2021-12-28
journal: bioRxiv
DOI: 10.1101/2021.12.28.474244
sha: 05b384ad5385a006cf9e5413ffff5738499f7ca5
doc_id: 999498
cord_uid: lz8hm06n

The emergence of SARS-CoV-2 variants of concern (VOCs) that escape pre-existing antibody neutralizing responses increases the need for vaccines that target conserved epitopes and induce cross-reactive B- and T-cell responses. We used a computational approach and sequence alignment analysis to design a new-generation subunit vaccine targeting conserved sarbecovirus B- and T-cell epitopes from Spike (S) and Nucleocapsid (N) to antigen-presenting cells expressing CD40 (CD40.CoV2). We demonstrate the potency of CD40.CoV2 to elicit high levels of cross-neutralizing antibodies against SARS-CoV-2, VOCs, and SARS-CoV-1 in K18-hACE2 transgenic mice, associated with improved viral control and survival after challenge. In addition, we demonstrate the potency of CD40.CoV2 in vitro to recall human multi-epitope, functional, and cytotoxic SARS-CoV-2 S- and N-specific T-cell responses that are unaffected by VOC mutations and cross-reactive with SARS-CoV-1 and, to a lesser extent, MERS epitopes. Overall, these findings provide a framework for a pan-sarbecovirus vaccine.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged in late 2019 64 in the Hubei province of China, has caused devastating human and economic losses 65 worldwide. Unprecedented mobilization of the scientific community has led to the 66 implementation of viral diagnostics, immunological monitoring tools, and the rapid 67 We have recently reported results on the efficacy of a new generation of subunit vaccines 117 targeting the RBD of the SARS-CoV-2 spike protein to the CD40 receptor (aCD40.RBD) 118 (Marlin et al., 2021) . We demonstrated that a single dose of the aCD40.RBD vaccine, injected 119 without adjuvant, is sufficient to boost a rapid increase in neutralizing antibodies in 120 convalescent non-human primates (NHPs) infected six months previously with SARS-CoV-2. 121

Interestingly, the aCD40.RBD vaccine-elicited antibodies cross-neutralized D614G SARS-122

CoV-2 and the VOCs Alpha (B1.1.7) and, to a lesser extent, Beta (B1.351). This vaccination 123 significantly improved protection against a new high-dose virulent challenge versus that in non-124 vaccinated convalescent animals (Marlin et al., 2021) . 125

Drawing from this knowledge, we used in silico approaches to design a next-generation CD40-126 targeting vaccine, CD40.CoV2, including new T-and B-cell epitopes spanning sequences from 127 S and nucleocapsid (N) proteins from SARS-CoV-2 and highly homologous to 38 128 sarbecoviruses, including SARS-CoV-2 VOCs. We report here the immunogenicity and 129 antiviral efficacy of this vaccine in a preclinical model. Moreover, the level of cytokines produced by activated monocytes/macrophages and DCs 259 (TNF, MIP-1, MIP-1 and IL-12p70) and those specific to cytotoxic activity (Granzyme B) 260 also increased. Interestingly, Th1 (IFN-, IL-2), Th2 (IL-4, IL-13), and Th17 (IL-17A) cytokines 261 were also detected. By contrast, stimulation with the matched vOLPmix only significantly 262 induced the production of IL-2 ( Figure 4) . 263

Overall, these results demonstrate the potency of minute amounts of CD40.CoV2 vaccine to 264 promote the recall of functional specific memory T and B cells. 265

We next confirmed the potency of the CD40.CoV2 vaccine construct to elicit cross-reactive 268 functional memory T cells against individual vaccine regions from SARS-CoV-2 Wuhan or 269 those harboring VOC/VOI mutations within these regions and SARS-CoV-1 S1/RBD/N2 Figure S4 ). Specific CD4 + and, 278 to a lesser extent, CD8 + T cells produced IFN-γ against all vaccine antigens but not against 279 control antigens (non-significant P value for control antigens vs the unstimulated condition, 280

Wilcoxon U test). The CD40.CoV2 vaccine recalled polyepitope IFN-γ + responses ranked from 281 vS1 > vRBD > vN2 > vS2 for CD4 + T cells and vN2 > vRBD > vS1 for CD8 + T cells ( Figure  282 5C). We also observed significant specific TNF + and IL-2 + CD4 + T-cell responses against 283 various vaccine antigens, whereas only the IL-2 + CD8 + T-cell response was significant after 284 stimulation with vRBD ( Figure S4 ). Interestingly, the strongest CD8 + T-cell response was 285 directed against vN2, known to be important for long-term immunity (Lineburg et al., 2021 ) 286 ( Figure 5C ). Finally, vaccine-expanded specific memory CD8 + T cells from three different 287 patients showed cytotoxic activity against autologous cells pulsed with different vOLPs (vN2 288 or vRBD), whereas there was no cytotoxic activity when target cells were pulsed with cont.OLP 289 (N1-N2 or M) ( Figure 5D ). 290

We also observed that CD40.CoV2 vaccine-expanded in-vitro CD4 + and CD8 + T-cell 291 responses were not affected when the cells were stimulated with RBD OLPs containing 292 common mutations of VOCs) and  (VOI) ( Figure 6A) . The cross-reacting CD8 + and 293

CD4 + T-cell responses were polyfunctional, simultaneously producing up to 2 or 3 cytokines, 294 respectively, with no major differences between VOCs ( Figure 6B ). 295

Finally, we re-stimulated CD40.CoV2-stimulated PBMCs from convalescent COVID-19 296 patients with OLPs covering the S1 (S1-CoV-1), vRBD (vRBD-CoV-1), and vN2 (vN2-CoV-1) 297 regions from SARS-CoV-1 and S1 from MERS. The vaccine elicited a high frequency of cross-298 reactive SARS-CoV-1 CD4 + and CD8 + T cells and, to a lower extent, cross-reactive MERS-S1 299 CD8 + T cells (Figure 7) . Interestingly, the CD40.CoV2 vaccine-induced SARS-CoV-1-and 300 SARS-CoV-2-specific T-cell responses were highly correlated for all corresponding antigen 301 sequences ( Figure S5 ). Overall, we confirm that the breadth of recall responses induced by 302 the CD40.CoV2 vaccine is not affected by RBD mutations from SARS-CoV-2 VOCs and fully 303 recognizes SARS-CoV-1 epitopes. 304 305 306

Despite the rapid development of several effective vaccines against SARS-CoV-2, recent 308 observations from vaccine campaigns in the general population have shown that the antibody 309 response is waning, with reduced efficacy against VOCs. Most are characterized by mutations 310 found in areas that are likely targeted by neutralizing antibodies, leading to vaccine escape 311 and compromising the first line of immunological defense against SARS-CoV-2. Moreover, 312

whether the current first-generation vaccines based on the original virus strain would still 313 protect against emerging VOCs or pre-emergent coronaviruses, which may be responsible for 314 future pandemics, is unknown. Thus, the development of new-generation vaccines that can 315 induce B-and T-cell responses to a broad range of epitopes, less prone to variation, are 316

Here, we demonstrate the immunogenicity and anti-viral efficacy of a new protein vaccine 318 composed of three regions from S (aa 125-250, 318-541, 1056-1209) and one from N (aa 276-319 411) of SARS-CoV-2, accumulating a large set of predicted CD4 + and CD8 + T-and B-cell 320 epitopes that are highly homologous to those of SARS-CoV-1 and 32 recently described 321 SARS-CoV-2-related coronaviruses. The CD40.CoV2 vaccine elicited potent SARS-CoV-2-322 specific cross-reactive and neutralizing antibodies associated with anti-viral and protective 323 activity against SARS-CoV-2 challenge in the hCD40/K18-hACE2 mouse model. Furthermore, 324 vaccinated mice developed high neutralizing antibody levels against the RBD region from not 325 only SARS-CoV-2 Wuhan but also several SARS-CoV-2 VOCs/VOI ( and ) and S 326 from SARS-CoV-1. These results confirm and extended our previous observations of the 327 antiviral efficacy of the CD40.RBD vaccine in convalescent macaques (Marlin et al., 2021) . 328

Our vaccine design was also driven by the need to include conserved epitopes to generate 329 robust memory CD4 + or CD8 + T cells to provide early control of acute infection with a novel (Tables S2 and S3 ). Accordingly, we found that in-vitro stimulation with the CD40.CoV-360 2 vaccine elicited specific cross-reactive polyfunctional CD4 + and CD8 + T-cell responses 361 against RBD from VOCs/VOI. Similarly, we found that the breadth of vaccine-elicited CD4 + and 362

CD8 + T-cell responses extended to S1, RBD, and N sequences from SARS-CoV-1. Indeed, 363 expanded CD8 + T cells were even cross reactive to S1 peptides from MERS, despite low 364 homology with SARS-CoV-2 (15%). 365

While it is critical to determine to what extent VOCs may or may not be susceptible to evading 366 existing humoral responses, T-cell associated immunity is, in general, significantly more 367 difficult for viruses to overcome, due to the broad and adaptable response generated in a given generally, all 38 sarbecoviruses tested, with up to 80-100% homology for the most highly 387

conserved T-cell epitopes (Tables S2 and S3 ). Moreover, we show that nine CD8 + T-cell 388 epitopes, from S and N, contained in the vaccine are 100% homologous among all 389 sarbecoviruses (Table S5) . Globally, these results confirm that vaccine sequences, particularly 390 vS2 and vN2, are theoretically suitable for the design of a pan-sarbecovirus vaccine aiming to 391 elicit broad cross-reactive T-cell responses. 392

We further propose in this vaccination strategy to deliver the antigens through a DC-targeting 393 platform, as the antigens were fused to a humanized anti-CD40 monoclonal antibody. This 394 platform has already been tested in vitro, in various preclinical animal models, and is currently 395 to 12 post infection (pi). The mean ± SD is presented. A Mann-Whitney U test was conducted 494 to compare differences in weight between the two groups on day 12 (n = 9-12 animals per 495 group) (**P < 0.01). Kaplan-Meier survival curves were generated (n = 6-9 animals per group) 496 and the P value was calculated using the log-rank (Mantel-Cox) test (*P < 0.05). (C) Viral load 497 (genome equivalent/g RNA) and viral infectious particle units (PFU/mg of tissue) in the lungs 498 was computed using the Euclidean distance and Ward's method (Ward, 1963) . Frequency of total cytokines (IFN-γ ± IL-2 ± TNF) produced by specific CD4 + (blue) or CD8 + 574 (green) T cells after in-vitro stimulation with the CD40.CoV2 vaccine (1 nM) on D0 and re-575 stimulation with OLPs representing the sequences of S1, vRBD, and vN2 from (A) SARS-CoV-576 1 and (B) S1 from MERS (1 µg/mL). Median values ± IQRs are shown. The Wilcoxon U test 577 was used for comparisons (**P < 0.01, ***P < 0.001, ns: not significant). 578

Further information and requests for resources should be directed to and will be fulfilled by the 583 lead contact, Yves Lévy (yves.levy@aphp.fr). 584

The CD40.CoV2 vaccine generated in this study was deposited in GenBank: anti-human CD40 586 

Any additional information required to reanalyze the data reported in this paper is available 598 from the lead contact upon request. genotyping, and production of hCD40/K18-hACE2 was performed at the CIPHE. Animals were 619 housed in groups and fed standard chow diets. 620

We enrolled a subgroup of COVID-19 patients of the prospective French COVID cohort 622 (registered at clinicaltrials.gov NCT04262921) in this study. Ethics approval was given on 623

February 5, 2020, by the French Ethics Committee CPP-Ile-de-France VI (ID RCB: 2020-624 A00256-33). Eligible patients were those who were hospitalized with virologically confirmed 625 COVID-19. Convalescent follow-up visits were performed between one, three, and six months 626 after infection. The study was conducted with the understanding and consent of each 627 participant or their surrogate covering the sampling, storage, and use of biological samples. 628

The vaccine was produced using the expression plasmids described in materials availability of 15-mer peptides, overlapping by 11 amino acids, covering the S1 region sequence of SARS-736

CoV-1: S1-CoV-1 (156 peptides). A pool of 15-mer peptides, overlapping by 11 amino acids, 737 covering the S1 region sequence of MERS: S1-MERS (168 peptides). As controls (cont.OLP), 

Preliminary Identification of Potential 876 Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS

Safety and 880 Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Gapped sequence alignment using artificial neural 883 networks: application to the MHC class I system

T-Cell and Antibody Responses to First BNT162b2 886

Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare 887 Workers: A Multicentre, Prospective

CD8+ T cells contribute to survival in 890 patients with COVID-19 and hematologic cancer

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 893 vaccine for preventing severe outcomes in Israel: an observational study

Immunoinformatics-aided identification of T cell and B cell 896 epitopes in the surface glycoprotein of 2019-nCoV

Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage 899 responsible for the COVID-19 pandemic

DC Subsets Regulate

Humoral Immune Responses by Supporting the Differentiation of Distinct Tfh Cells. Front. 903 Immunol. 10

Broadly 905 neutralizing antibodies overcome SARS-CoV-2 Omicron 2 antigenic shift

Anti-CD40 Antibodies Fused to CD40 Ligand Have Superagonist 908 Properties

Omicron extensively but incompletely 911 escapes Pfizer BNT162b2 neutralization

Internalization and endosomal 914 degradation of receptor-bound antigens regulate the efficiency of cross presentation by 915 human dendritic cells

Learning from HIV-1 to predict the 963 immunogenicity of T cell epitopes in SARS-CoV-2

CoV-2 variants escape neutralization by vaccine-induced humoral immunity

TLR-9 agonist and CD40-targeting vaccination 970 induces HIV-1 envelope-specific B cells with a diversified immunoglobulin repertoire in 971 humanized mice

Targeting dendritic cells in 974 humanized mice receiving adoptive T cells via monoclonal antibodies fused to Flu epitopes

Targets of T Cell Responses to 978 SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

-2 human T cell epitopes: Adaptive immune response against COVID-19

Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell 984 immunity in naïve and COVID-19 recovered individuals

Immunogenicity of BNT162b2 987 vaccine Against the Alpha and Delta Variants in Immunocompromised Patients

SARS-CoV-2 Cell Entry 991 Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

SARS-CoV-2 variants B.1.351 995 and P.1 escape from neutralizing antibodies

Identification of cross-reactive CD8+ T cell receptors with high functional 998 avidity to a SARS-CoV-2 immunodominant epitope and its natural mutant variants

In silico identification of vaccine targets for 2019-1001 nCoV

Elapsed time since BNT162b2 vaccine and risk of SARS-1004

CoV-2 infection in a large cohort (Infectious Diseases (except HIV/AIDS))

Improved methods for predicting peptide binding affinity 1007 to MHC class II molecules

BepiPred-2.0: improving 1009 sequence-based B-cell epitope prediction using conformational epitopes

Early T cell and binding 1012 antibody responses are associated with COVID-19 RNA vaccine efficacy onset

SARS-CoV-2-specific CD8+ T cell responses in 1016 convalescent COVID-19 individuals

Omicron SARS-CoV-2 variant: a new chapter in the 1018 COVID-19 pandemic

Current status of therapeutic monoclonal 1020 antibodies against SARS-CoV-2

Evidence for increased breakthrough rates of 1023 SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals

Identifying SARS-CoV-2-related coronaviruses in 1027 Malayan pangolins

SARS-CoV-2-specific T cell immunity in cases of 1030 COVID-19 and SARS, and uninfected controls

Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with 1034 Neutralizing Antibody Generation

Long-Term Persistence of Robust Antibody and Cytotoxic T Cell Responses in 1037 Recovered Patients Infected with SARS Coronavirus

CD8+ T cells specific for an 1040 immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal 1041 coronaviruses

Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus 1044 Particles

Efficacy of the

Covid-19 Vaccine against the B.1.351 Variant

CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in 1051 convalescent macaques

Selective and cross-reactive SARS-CoV-2 T cell 1054 epitopes in unexposed humans

First-dose mRNA vaccination is 1057 sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have 1058 recovered from COVID-19

Correlates of protection against SARS-CoV-2 in 1061 rhesus macaques

A SARS-like cluster of 1064 circulating bat coronaviruses shows potential for human emergence

SARS-like WIV1-CoV 1068 poised for human emergence

SARS-CoV-2 spike L452R variant evades cellular 1071 immunity and increases infectivity

Structure-guided T cell vaccine 1074 design for SARS-CoV-2 variants and sarbecoviruses

SARS-CoV-2-derived peptides define 1077 heterologous and COVID-19-induced T cell recognition

Rapid induction of antigen-1080 specific CD4+ T cells is associated with coordinated humoral and cellular immune responses 1081 to SARS-CoV-2 mRNA vaccination

Broad and strong memory CD4+ and CD8+ T cells induced 1084 by SARS-CoV-2 in UK convalescent individuals following COVID-19

Considerable escape of 1088 SARS-CoV-2 Omicron to antibody neutralization

Sequence-based prediction 1091 of SARS-CoV-2 vaccine targets using a mass spectrometry-based bioinformatics predictor 1092 identifies immunogenic T cell epitopes

Identification and validation of 174 COVID-19 vaccine candidate 1095 epitopes reveals low performance of common epitope prediction tools

Humoral and T-cell responses to SARS-1098

CoV-2 vaccination in patients receiving immunosuppression

Comparison of two highly-effective 1102 mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence

Minimal cross-over between mutations 1105 associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in 1106 COVID-19 convalescent individuals

PD-1-Expressing SARS-CoV-2-Specific CD8+ T Cells Are Not 1109 Exhausted, but Functional in Patients with COVID-19

SPICE: Exploration and analysis of post-1111 cytometric complex multivariate datasets

529 variant (Omicron) evades neutralization by sera from vaccinated and convalescent 1114 individuals (Infectious Diseases

COVID-19 vaccine BNT162b1 elicits human 1117 antibody and TH1 T cell responses

Characterization of pre-existing and induced 1120 SARS-CoV-2-specific CD8+ T cells

Adaptive immunity to SARS-CoV-2 and COVID-19

Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell Receptors

mRNA vaccination boosts 1129 cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Early induction of functional SARS-CoV-1133 2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 1134 patients

Tracking 1136

Immune Cell Proliferation and Cytotoxic Potential Using Flow Cytometry

Impact of SARS-CoV-2 variants on the total CD4+ 1140 and CD8+ T cell reactivity in infected or vaccinated individuals

Comprehensive analysis of T cell 1144 immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases

Sixteen novel lineages of SARS-1148

CoV-2 in South Africa

Genomic 1150 Characterization of a Novel SARS-CoV-2 Lineage from Rio de Janeiro

Evidence for SARS-CoV-2 1154 related coronaviruses circulating in bats and pangolins in Southeast Asia

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. 1158

Hierarchical Grouping to Optimize an Objective Function

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute 1164 respiratory distress syndrome

SARS-CoV-2 1167 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

A new coronavirus associated with human respiratory disease in 1171 China

Impact on disease mortality of clinical, biological, and virological characteristics at 1175 hospital admission and overtime in COVID-19 patients

Functional Specialty of CD40 and Dendritic Cell Surface 1178 Lectins for Exogenous Antigen Presentation to CD8+ and CD4+ T Cells

A pneumonia outbreak associated with a new coronavirus of 1182 probable bat origin

Superiority in Rhesus Macaques of 1185

Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-1186

Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses